TNFSF14 and neoplasm: In the current manuscript, we report the results of an experimental therapy targeting orthotopically-induced PDAC lesions in immunocompetent mice using recombinant oncolytic MYXV encoding mouse tumor necrosis factor ligand superfamily member 14 (also called LIGHT), designed to boost the anti-tumor immune response induced by the virotherapy.